Camrelizumab (Camre) plus taxane-based chemotherapy (CT): Clinical outcomes and dynamic monitoring of CEA as a predictive biomarker of response in patients with recurrent or advanced esophageal squamous cell carcinoma (ESCC).

被引：0
|
作者：
Kong, Cheng
Xu, Jianhua
Jiang, Ming
Zhu, Xiangzhi
Ye, Jinjun
Yu, Shaorong
Zhu, Jun
机构：
[1] Jiangsu Canc Hosp, Nanjing, Peoples R China
[2] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Radiat Oncol, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16524
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy
    Qiu, Jianjian
    Lin, Hancui
    Yu, Yilin
    Ke, Dongmei
    Li, Hui
    Zheng, Hongying
    Zheng, Qunhao
    Wang, Zhiping
    Lin, Mingqiang
    Yang, Jun
    Liu, Lingyun
    Zhang, Mengyan
    Liu, Tianxiu
    Wu, Yahua
    Li, Jiancheng
    Lai, Jinhuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (04) : 550 - 564
  • [22] Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy
    Jianjian Qiu
    Hancui Lin
    Yilin Yu
    Dongmei Ke
    Hui Li
    Hongying Zheng
    Qunhao Zheng
    Zhiping Wang
    Mingqiang Lin
    Jun Yang
    Lingyun Liu
    Mengyan Zhang
    Tianxiu Liu
    Yahua Wu
    Jiancheng Li
    Jinhuo Lai
    International Journal of Clinical Oncology, 2023, 28 : 550 - 564
  • [23] A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR
    Chunsheng Wang
    Kewei Zhao
    Shanliang Hu
    Yong Huang
    Li Ma
    Yipeng Song
    Minghuan Li
    BMC Cancer, 20
  • [24] A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR
    Wang, Chunsheng
    Zhao, Kewei
    Hu, Shanliang
    Huang, Yong
    Ma, Li
    Song, Yipeng
    Li, Minghuan
    BMC CANCER, 2020, 20 (01)
  • [25] A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N plus I) or nivolumab plus chemotherapy (N plus CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.
    Chau, Ian
    Bridgewater, John A.
    Wyrwicz, Lucjan
    Greenwood, Mike
    Blum, Steven I.
    Moreno-Koehler, Alejandro
    Worthy, Gill
    Taylor, Fiona
    Davis, Catherine
    Chen, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 251 - 251
  • [26] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
    Lei, Ming
    Doki, Yuichiro
    Kitagawa, Yuko
    Kato, Ken
    Chau, Ian
    Yao, Jin
    Xu, Jianming
    Wyrwicz, Lucjan S.
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez
    Holtved, Eva
    Blum Murphy, Mariela A.
    Novosiadly, Ruslan
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
  • [27] M1a Nodal Involvement and Induction Taxane-Based Chemotherapy Before Neoadjuvant Chemoradiation Therapy Are Associated With Survival Outcomes in Pathological Complete Responder After Trimodality Treatment for Esophageal Squamous Cell Carcinoma
    Lu, S. L.
    Hsu, F. M.
    Tsai, C. L.
    Lee, J. M.
    Huang, P. M.
    Hsu, C. H.
    Lin, C. C.
    Chang, Y. L.
    Hsieh, M. S.
    Cheng, J. C. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S153 - S153
  • [28] Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
    Li, Ying
    Ji, Yanyan
    Shen, Lin
    Yin, Xudong
    Huang, Tianyu
    Deng, Bin
    Guo, Hong
    Wu, Yunjiang
    Chen, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study
    Li, Y.
    Zhou, A.
    Liu, S.
    He, M.
    Chen, K-N.
    Tian, Z.
    Chen, H.
    Tian, H.
    Yu, Y.
    Qu, W.
    Xue, L.
    Wang, S.
    Bie, F.
    Zhou, B.
    Huang, H. Y.
    Fang, Y.
    Li, B.
    Dai, X.
    Gao, S.
    He, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1101 - S1101
  • [30] Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis
    Huang, J.
    Liu, Y.
    Dai, S.
    Lu, P.
    Ba, Y.
    Wu, L.
    Bai, Y.
    Zhang, S.
    Feng, J.
    Cheng, Y.
    Li, J.
    Wen, L.
    Yuan, X.
    Ma, C.
    Fan, Q.
    Wang, X.
    Xu, B.
    ANNALS OF ONCOLOGY, 2016, 27
12345